These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 39086574)

  • 1. Clinical Profile and Efficacy of Long-Acting Octreotide in Hyperinsulinemic Hypoglycaemia.
    Kubsad PS; Vani HN; Sheshadri T; Palany R
    Indian J Endocrinol Metab; 2024; 28(3):289-294. PubMed ID: 39086574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of congenital hyperinsulinism with long-acting release octreotide.
    Le Quan Sang KH; Arnoux JB; Mamoune A; Saint-Martin C; Bellanné-Chantelot C; Valayannopoulos V; Brassier A; Kayirangwa H; Barbier V; Broissand C; Fabreguettes JR; Charron B; Thalabard JC; de Lonlay P
    Eur J Endocrinol; 2012 Feb; 166(2):333-9. PubMed ID: 22048969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
    Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion.
    Lustig RH; Greenway F; Velasquez-Mieyer P; Heimburger D; Schumacher D; Smith D; Smith W; Soler N; Warsi G; Berg W; Maloney J; Benedetto J; Zhu W; Hohneker J
    Int J Obes (Lond); 2006 Feb; 30(2):331-41. PubMed ID: 16158082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.
    Gillis JC; Noble S; Goa KL
    Drugs; 1997 Apr; 53(4):681-99. PubMed ID: 9098666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
    Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
    Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China].
    Xuan JW; Zhang ZY; Wang YF; Mao ZG; Lu YJ; Wang RZ
    Zhonghua Yi Xue Za Zhi; 2017 Mar; 97(10):765-769. PubMed ID: 28316158
    [No Abstract]   [Full Text] [Related]  

  • 10. Paradoxical hypoglycaemia associated with diazoxide therapy for hyperinsulinaemic hypoglycaemia.
    Ponmani C; Gannon H; Hussain K; Senniappan S
    Horm Res Paediatr; 2013; 80(2):129-33. PubMed ID: 23886961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    Yang LP; Keating GM
    Drugs; 2010 Sep; 70(13):1745-69. PubMed ID: 20731479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of long-acting octreotide for intractable chronic gastrointestinal bleeding in children.
    O'Meara M; Cicalese MP; Bordugo A; Ambrosi A; Hadzic N; Mieli-Vergani G
    J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):48-53. PubMed ID: 25162361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
    Penning C; Vecht J; Masclee AA
    Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour.
    Abell SK; Teng J; Dowling A; Hofman MS; MacIsaac RJ; Sachithanandan N
    Endocrinol Diabetes Metab Case Rep; 2015; 2015():140097. PubMed ID: 25755880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.
    Mystakidou K; Katsouda E; Tsilika E; Smyrniotis V; Vassiliou I; Tsiatas M; Vlahos L
    Anticancer Res; 2006; 26(3B):2325-8. PubMed ID: 16821610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
    Jenkins PJ; Akker S; Chew SL; Besser GM; Monson JP; Grossman AB
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping.
    Arts J; Caenepeel P; Bisschops R; Dewulf D; Holvoet L; Piessevaux H; Bourgeois S; Sifrim D; Janssens J; Tack J
    Clin Gastroenterol Hepatol; 2009 Apr; 7(4):432-7. PubMed ID: 19264574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.